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INTRODUCTION
In organ transplantation, CD4 + but not CD8 + T cells are essential for allo-rejection, as it has been shown that CD4 + T cells are necessary and sufficient for mediating acute rejection of heart and kidney allografts (Bolton et al., 1989; Krieger et al., 1996) . Among CD4 + T cell subsets, alloreactive T helper 1 (Th1) cells have been shown to cause allograft damage directly through Fas-Fas ligand-mediated cytotoxicity, or indirectly through inducing delayed type hypersensitivity by macrophages and promoting the activity of cytotoxic CD8 + T cells (Liu et al., 2013) . Th17 cells also mediate allograft rejection, which has been demonstrated in recipient mice lacking T-bet, the master regulator of Th1 cell differentiation (Yuan et al., 2008) . T follicular helper (Tfh) cells contribute to allograft rejection by promoting alloantibody responses (Conlon et al., 2012) . By contrast, CD4 +
Foxp3
+ regulatory T (Treg) cells protect the transplanted organs from rejection in many experimental models (Miyahara et al., 2012; Safinia et al., 2015) . T cell dysfunction, such as exhaustion and anergy, represents distinct T cell differentiation states following antigen encounter (Schietinger and Greenberg, 2014) . The dysfunctional differentiation of T cells involves the transcriptional induction of essential negative regulators that inhibit T cell function (Fathman and Lineberry, 2007; Wherry and Kurachi, 2015) . For instance, dysfunctional T cells that arise during certain chronic infections and cancers sustainably express various inhibitory receptors, including programmed cell death protein 1 (PD-1), CD160, lymphocyte-activation gene 3 (LAG3), B and T lymphocyte attenuator (BTLA), and cytotoxic T lymphocyte antigen 4 (CTLA-4) (Crawford et al., 2014; Schietinger et al., 2016) . These receptors exert inhibitory effects on T cell function, and blockade of PD-1, programmed deathligand 1 (PD-L1), or CTLA-4 has been successfully used to treat several cancer types by reversing T cell dysfunction (Zarour, 2016) . Transcription factors T-bet, Blimp-1, NFAT, and FOXO1 regulate PD-1 expression and have been implicated in T cell exhaustion and dysfunction (Wherry and Kurachi, 2015) .
Interferon regulatory factor 4 (IRF4) is a member of the IRF family of transcription factors and is preferentially expressed in hematopoietic cells. It plays essential roles in many aspects of T cell, B cell, and dendritic cell differentiation and function (Huber and Lohoff, 2014; Ochiai et al., 2013; Vander Lugt et al., 2014) . In T cells, IRF4 is promptly expressed within hours following TCR stimulation, and its expression level is TCR affinity dependent (Man et al., 2013) . IRF4 controls the differentiation of Th2, Th9, Th17, Tfh, Treg, and cytotoxic effector CD8 + T cells (Bollig et al., 2012; Br€ ustle et al., 2007; Cretney et al., 2011; Huber et al., 2008; Staudt et al., 2010; Yao et al., 2013; Zheng et al., 2009 ). Irf4-deficient T cells exhibit a severe functional defect in T cell-mediated responses, including microbial infection, allergy, graft-versus-host reaction, and autoimmunity (Br€ ustle et al., 2007; Grusdat et al., 2014; Huber and Lohoff, 2014; Mittr€ ucker et al., 1997; Staudt et al., 2010) .
Here we examined the role of IRF4 in transplant rejection and acceptance. We found that all fully MHC-mismatched heart allografts survived indefinitely in Irf4-deficient mice. This stable engraftment in Irf4-deficient recipients involved the progressive establishment of effector CD4 + T cell dysfunction. Mechanistically, IRF4 repressed a group of previously defined molecules associated with CD4 + T cell dysfunction, including PD-1 and Helios. In particular, in the absence of IRF4, chromatin accessibility and binding of Helios at PD-1 cis-regulatory elements were increased, resulting in enhanced PD-1 expression and CD4 + T cell dysfunction. Although the dysfunctional state of Irf4-deficient T cells was initially reversible by blockade of PD-1-PD-L1 pathway, it progressively evolved into a ''terminal'' irreversible state within 30 days post-transplant. Taken together, our results revealed that IRF4 repressed the dysfunctional differentiation of CD4 + T cells. Induction of T cell dysfunction by targeting IRF4 during transplantation may be a therapeutically relevant strategy for achieving transplant acceptance.
RESULTS

IRF4 Is Highly Induced in Graft-Infiltrating T Cells and Is
Required for Heart Transplant Rejection IRF4 is a key transcription factor for translating TCR signaling into proper T cell responses (Huber and Lohoff, 2014) , but its role in T cell-mediated transplant rejection remains unclear.
Here we first assessed IRF4 expression in T cells in response to heart transplantation. BALB/c hearts were transplanted into fully MHC-mismatched C57BL/6 (B6) recipients. Splenocytes and graft-infiltrating cells were harvested and analyzed at 7 days post-transplant when heart allografts were rejected. We found that graft-infiltrating T cells expressed a significantly high mean fluorescence intensity (MFI) of IRF4, while splenic T cells from transplanted mice had a moderate increase in IRF4 expression compared to that of naive B6 mice (Figures 1A and 1B) . The majority of graft-infiltrating T cells had lost CD62L expression but expressed T cell activation markers CD44, glucose transporter 1 (GLUT1), and CD98 (Figures S1A and S1B). Thus, IRF4 was highly expressed in graft-infiltrating T cells and was correlated to the activation status of these cells.
To investigate whether IRF4 expression in T cells plays a role in transplant rejection, we transplanted BALB/c hearts into T cellspecific IRF4 knockout (Irf4 fl/fl Cd4-Cre; B6 background) or wild-type (WT) B6 mice. None of the Irf4 fl/fl Cd4-Cre mice rejected their BALB/c heart allografts (median survival time [MST] of > 100 days; n = 6), whereas WT B6 mice rejected BALB/c hearts acutely (MST = 7.17 ± 0.41 days; n = 6) (Figure 1C) . Histology of heart allografts harvested from Irf4 Cd4-Cre mice were transplanted with BALB/c hearts. (C) The percentage of allograft survival after transplantation (n = 6). **p < 0.01; Mann-Whitney test. (D) H&E-stained sections of heart allografts harvested from WT B6 recipients at day 7 post-transplant, or from Irf4 fl/fl Cd4-Cre recipients at day 7 or day 100 posttransplant. Three mice per group were analyzed, with ten graft sections per mouse. Two representative images (top and bottom) per group are shown. See also Figure S1 .
vasculopathy ( Figure 1D ). Hence, selective ablation of IRF4 in T cells abrogated their ability to reject heart allografts, which provides a potential prospect for achieving graft acceptance. jected the heart allografts ( Figure 2A ). These results indicated that in our model the lack of functional CD4 + (but not CD8 + )
IRF4 Is Critical in T Cell
T cells was essential for heart allograft acceptance and that increasing the number of dysfunctional Irf4-deficient CD4 + T cells failed to restore transplant rejection. CD4 + CD25 + Foxp3 + Treg cells are essential to maintain longterm allograft survival in many experimental models (Miyahara et al., 2012 in WT recipients at day 9 post-transplant ( Figure S1D ). Hence, IRF4 was essential for the induction of Tfh cell response to heart transplant. An adoptive co-transfer model was used to further assess the intrinsic changes of Irf4-deficient T cells. CD45.1 + WT T cells and CD45.2 + Irf4 -/-T cells were co-injected at a 1:1 ratio into
B6.Rag1
-/-mice 1 day before receiving BALB/c heart allografts ( Figure 2C ). The heart grafts were rejected between 9 and 15 days after transplant. At day 9 post-transplant, about 30% transferred cells in spleens were Irf4 -/-T cells ( Figure 2D Figure 2F ). In addition, the frequencies of IFN-g-and IL-17-producing cells within CD4 + Irf4 -/-T cells were significantly lower than those of CD4 + WT T cells ( Figure 2G ), and the frequency of IFN-g-producing cells within CD8 + Irf4 -/-T cells was also lower than that of CD8 + WT T cells ( Figure 2H ). Thus, IRF4 deficiency inhibited the expression of effector T cell markers and the production of signature cytokines for effector T cells in response to heart transplantation. The frequency of Foxp3 + cells within CD4 + Irf4 -/-splenic T cells was lower than that of CD4 + WT splenocytes ( Figure 2G ). Next, we repeated these experiments by separately transferring sorted CD4 + WT,
-/-mice 1 day prior to BALB/c heart transplantation ( Figure S2A and expressed less Foxp3 ( Figure S2E ). Taken together, IRF4 promoted effector T cell differentiation and infiltration into heart allografts. (Martinez et al., 2012; Wherry and Kurachi, 2015) and also expressed similar or slightly lower MFIs of BTLA and CTLA-4. Profoundly, another essential exhaustion marker, LAG-3, was significantly decreased on Irf4 -/-CD4 + T cells ( Figure 3A ). We used microarray analysis to compare the gene expression profiles between Irf4 Data are mean ± SD. **p < 0.01; unpaired Student's t test. Data are representative of three independent experiments with three to four mice in each group (C-H). See also Figure S2 . quantitative real-time PCR ( Figure 3D ). Helios is a signature protein for T cell dysfunction (Crawford et al., 2014; Singer et al., 2016) . We found that Helios protein was absent in activated WT CD4 + T cells but was expressed in more than 50% activated Irf4 -/-CD4 + T cells ( Figure 3E ). Collectively, IRF4 repressed a group of previously defined molecules associated with CD4 + T cell dysfunction.
IRF4 Represses a Group of Molecules
IRF4 Represses CD4 + T Cell Expression of PD-1
Given that Pdcd1 was among the highest upregulated genes in Irf4 -/-versus WT CD4 + T cells after activation, we aimed to understand the regulation of PD-1 expression by IRF4. We observed that PD-1 expression on Irf4 -/-CD4 + T cells was progressively increased from day 0 to day 3 upon in vitro activation ( Figure 4A ) and was much higher than that of co-cultured CD45.1 + WT CD4 + T cells ( Figure 4B ). To further examine the role of IRF4 in PD-1 expression, activated Irf4 -/-CD4 + T cells were transduced with a retroviral vector expressing IRF4-green fluorescent protein (GFP) or a control vector expressing just GFP. As shown in Figure 4C , transduction of IRF4 into activated
Irf4
-/-CD4 + T cells (detected by GFP expression) led to a marked inhibition of PD-1 expression when compared with GFP control transduction. Thus, IRF4 expression in activated T cells mediated repression of PD-1.
To determine how IRF4 represses PD-1 expression, we performed chromatin immunoprecipitation (ChIP) analysis. In activated WT CD4 + T cells (expressing IRF4), we did not detect specific enrichment of IRF4 at the putative binding sites upstream of Pdcd1 or at a set of known cis-elements of Pdcd1, including two upstream conserved regions (CR-B and CR-C) as well as two regions located -3.7 and +17.1 kb from the Pdcd1 transcription start site ( Figure S3 ; Bally et al., 2016) . These data suggested that the repression effect of IRF4 on PD-1 expression was unlikely to be related to its transcriptional activity. We next investigated whether histone modifications are involved in the regulation of PD-1 expression by IRF4. As shown in Figure 4D , H3 acetylation (H3Ac) was significantly increased at the À3.7 site and the CR-B and CR-C regions, whereas H4 acetylation (H4Ac) and H3 lysine 4 trimethylation (H3K4me3) were markedly increased at the À3.7 site and the CR-C region in acti- Figure 4E ). We therefore investigated whether Helios regulates PD-1 expression. This possibility was supported by a ChIP assay, which detected the binding of Helios to the cis-elements of Pdcd1 in activated Irf4 -/-CD4 + T cells ( Figure 4F ).
Furthermore, activated WT CD4 + T cells (with minimal Helios expression) were transduced with a retroviral vector expressing Helios-GFP or just GFP. We found that transduction of Helios into activated WT CD4 + T cells resulted in a marked increase of PD-1 expression when compared with GFP control transduction ( Figure 4G ). Activated Irf4 -/-CD4 + T cells (with Helios expression) were also transduced with a retroviral vector co-expressing GFP and short hairpin RNA (shRNA) sequences for Helios (sh-Helios) or expressing GFP alone (sh-Ctrl). As indicated by GFP + cells, transduction with sh-Helios decreased PD-1 expres- Figure 4H ). Thus, Helios promoted PD-1 expression. Taken together, IRF4 deletion progressively increased PD-1 expression on activated T cells, which was associated with the increased chromatin accessibility and Helios binding to PD-1 cis-regulatory elements.
Dysfunctional State of Irf4-Deficient T Cells Is Initially Reversible by PD-L1 Blockade but It Progressively Develops into an Irreversible State TCR-transgenic TEa CD4
+ T cells (B6 background) recognize a BALB/c I-Ea allopeptide presented by B6 APCs; mice containing only TEa T cells were able to reject BALB/c skin allografts (Gupta et al., 2011) . We found that adoptive transfer of WT TEa but not Irf4 -/-TEa cells induced rejection of BALB/c hearts in Irf4 fl/fl Cd4-Cre recipients ( Figure 5A ). To determine whether immune checkpoint PD-1 contributes to the dysfunction of alloantigen-specific Irf4-deficient CD4 + T cells in transplantation, we assessed PD-1 expression on Irf4 -/-TEa versus WT TEa cells by transferring and tracking these cells in CD45.1 + B6 congenic mice. As shown in Figure 5B , CD45.1 + B6 mice were transferred with either CD45.2 + WT TEa or CD45.2 + Irf4 -/-TEa cells on day À1 and were transplanted with BALB/c hearts or left un-transplanted on day 0. Splenocytes were analyzed on day 6 ( Figure 5B ). In CD45.1 + B6 mice without BALB/c heart grafting, TEa CD4 + T cells neither proliferated nor expressed PD-1. In heart transplanted mice, Irf4 -/-TEa cells exhibited higher PD-1 expression and a lower proliferation rate than did WT TEa cells ( Figure 5B ). Thus, IRF4 deficiency promoted PD-1 expression on alloantigen-specific T cells, which was associated with decreased of five heart allografts in anti-PD-L1 mAb-treated recipients were rejected within 35 days, whereas all allografts survived more than 100 days in recipient mice treated with anti-CTLA-4 mAb alone or rat IgG. By contrast, all six heart allografts in recipient mice treated with both anti-PD-L1 and anti-CTLA-4 mAbs were rejected on days 7-8 after transplant ( Figure 5C ). Analysis of splenocytes at day 7 post-transplant revealed that anti-PD-L1 plus anti-CTLA-4 treatment increased expression of proliferation marker Ki67, metabolic activation makers CD98 and CD71, and effector cytokine IFN-g of Irf4-deficient CD4 + T cells ( Therefore, in this checkpoint-blockade model, the reversal of CD4 + (but not CD8 + ) T cell dysfunction was essential for restoring transplant rejection. We also transplanted BALB/c hearts into Irf4 fl/fl Cd4-Cre mice and treated them with both 200 mg anti-PD-L1 and 200 mg anti-CTLA-4 mAbs starting from day 0 (on days 0, 3, and 5), day 7 (on days 7, 10, and 12), or day 30 (on days 30, 33, and 35) after transplant. Immune checkpoint blockade starting from day 7 was not as potent as the treatment group starting from day 0, but still restored rejection of four of six heart allografts. Immune checkpoint blockade starting from day 30 after transplant did not restore allograft rejection in Irf4 fl/fl Cd4-Cre mice, and all five allografts survived more than 100 days ( Figure 5H ). Taken together, PD-1 was highly expressed by alloantigen-specific Figure 5I shows the transduction efficacy of IRF4-GFP. Irf4 fl/fl Cd4-Cre recipients injected with one million IRF4 re-introduced (but not GFP-control-transduced) Irf4 -/-CD4 + T cells acutely rejected heart allografts within 6 days ( Figure 5J) Helios were already highly expressed, and trametinib barely affects their expressions ( Figure S6E ). Moreover, 100 nM trametinib was sufficient to inhibit CD4 + T cell proliferation as well as Th1 and Th17 cell differentiation, but promoted the differentiation of inducible Treg cells ( Figures 7B and 7C ). Th1 and Th17 cells contribute to the pathogenesis of experimental autoimmune encephalomyelitis (EAE) (Rangachari and Kuchroo, 2013) . We thus investigated whether transient trametinib treatment would affect EAE development. Female WT mice were immunized with the MOG 35-55 peptide and treated with corn oil or 3 mg/kg trametinib every other day from day 0 to day 12. Control mice treated with corn oil developed EAE with a mean disease onset of 12.0 ± 0.47 days after immunization. By contrast, mice treated with trametinib were absolutely resistant to EAE and exhibited no incidence of disease, indicated by definite absence of loss of motor function or paralysis throughout the entire period of observation ( Figure 7D ). CD4 + T cell infiltration in the brain was dramatically decreased in mice treated with trametinib compared with corn oil controls, and the expression of cytokines GM-CSF, IFN-g, IL-17, and Foxp3 by brain infiltrating CD4 + T cells was significantly decreased (Figures 7E,  S7A , and S7B). The frequency of IL-17 + CD4 + T cells in the periphery was also lower in trametinib-treated mice than that of control mice ( Figure S7C ). We then examined whether trametinib is effective to prolong allograft survival. WT B6 mice were transplanted BALB/c hearts and treated with corn oil or 3 mg/kg trametinib every other day from day 0 to day 12. Trametinib-treated recipient mice displayed prolonged heart allograft survival (MST = 13.17 ± 0.75 days) compared with corn oil controls (MST = 7.33 ± 0.52 days) ( Figure 7F ). A TEa cell transfer model was applied to determine whether or not trametinib affects the PD-1 and Helios expressions of alloantigen-specific CD4 + T cells. CD45.1 + B6 mice were transferred with CD45.2 + TEa cells on day À1, transplanted with BALB/c hearts on day 0, and treated with corn oil or 3 mg/kg trametinib on day 0, 2, 4, and 6. On day 7 after transplant, splenocytes were analyzed. We found that trametinib promoted PD-1 and Helios expression on TEa cells in transplanted mice ( Figures 7G) . Collectively, these data indicated that trametinib effectively reduced IRF4 expression in activated T cells, inhibited Th1 and Th17 cell differentiation, abrogated EAE development, and prolonged heart allograft survival.
DISCUSSION
The transcriptional programs regulating allogeneic T cell responses and subsequent transplant outcomes (rejection versus acceptance) have not been adequately explored. In the present work, we found that all heart allografts survived indefinitely in mice when IRF4 was deleted in T cells. Further mechanistic investigation revealed that IRF4 repressed the expression of a group of molecules associated with T cell dysfunction, including PD-1 and Helios. Thus, Irf4-deficient CD4 + T cells displayed increased expression of these molecules and underwent differentiation to a dysfunctional fate. The initial dysfunctional state of Irf4-deficient T cells was reversible by immune checkpoint blockade, but its late dysfunctional state was irreversible. Therefore, IRF4 is a key transcriptional determinant that dictates effector T cell fate decisions; IRF4 deletion leads to the progressive establishment of CD4 + T cell dysfunction and long-term allograft survival. We found that all BALB/c heart allografts survived indefinitely in Irf4 fl/fl Cd4-Cre mice that were not treated with any immunosuppressive therapies. Of note, deficiency of several other molecules also allows T cell development but impairs T cell function, such as BATF, signal transducer and activator of transcription 3 (STAT3), nuclear factor kB subunit c-Rel, and IL-2-inducible T cell kinase (Itk) (Murphy et al., 2013; Notarangelo, 2013 hearts. Thus, lack of Th17 and Tfh cell differentiation is not sufficient to completely explain the severe dysfunction of Irf4-deficient T cells. c-Rel and Itk have been shown to control IRF4 expression in lymphocytes (Grumont and Gerondakis, 2000; Nayar et al., 2012) . The role of these two molecules in transplantation was either unknown or less significant than that of IRF4 observed in this study (Yang et al., 2002) . Previous reports showed that Irf4-deficient T cells do not expand properly upon antigen stimulation (Mahnke et al., 2016; Man et al., 2013) . We also found that T cell frequencies in the spleens of Irf4 fl/fl Cd4-Cre mice remained largely unchanged at day 7 after transplantation. Thus, the expansion of alloreactive T cells in those recipients was impaired. We further found that alloantigen-specific Irf4 -/-CD4 + T cells responded to heart allografts and expanded as indicated by CTV labeling, though they were generally found to be 2-to 4-fold less than the frequency of expanded WT alloantigen-specific CD4 + T cells. A major mechanistic finding in this study was that IRF4 repressed the expression of essential molecules associated with T cell dysfunction. Hence, IRF4 deletion in activated CD4 + T cells led to increased expression of PD-1, Helios, PLAGL1, CD160, CD73, and FR4, which are characteristic markers of dysfunctional T cells (Crawford et al., 2014; Fathman and Lineberry, 2007; Martinez et al., 2012; Wherry and Kurachi, 2015) . Given that PD-1 is a key immune checkpoint molecule implicated in T cell dysfunction, we investigated the regulation of PD-1 expression by IRF4. In the absence of IRF4, activated CD4 + T cells induced an active chromatin state at the critical cis-elements of Pdcd1, as well as the robust Helios expression. We then found that Helios bound to cis-elements of Pdcd1 and promoted PD-1 expression. Helios has been shown to be highly expressed by natural Treg cells, exhausted T cells, and tolerated T cells (Crawford et al., 2014; Kim et al., 2015; Ross et al., 2014; Singer et al., 2016) . It will be interesting to further define whether Helios sustains PD-1 expression in those cells. Transcription factors NFAT1, T-bet, FoxO1, and Blimp1 have also been shown to regulate PD-1 expression (Wherry and Kurachi, 2015) , but the connection between IRF4 and these molecules on Pdcd1 transcription will require further investigation. We attributed the initial dysfunction of Irf4-deficient T cells in transplantation to the presence of inhibitory checkpoints. PD-1 was highly expressed on alloantigen-specific Irf4-deficient T cells; blockade of its ligand, PD-L1, during the initial days post-transplant was capable of restoring the anti-allograft function of Irf4-deficient T cells. Activated Irf4-deficient T cells also expressed intracellular CTLA-4, though at a relatively low expression compared to that of activated WT T cells. Transient blockade of PD-L1 plus CTLA-4 during the initial days posttransplant synergistically and completely rescued the anti-allograft function of Irf4-deficient T cells by restoring their ability to undergo proliferation and IFN-g production. Thus, these two major inhibitory checkpoints operated as non-redundant pathways to mediate the dysfunction of Irf4-deficient T cells, likely due to their distinct mechanisms of action (Baumeister et al., 2016; Larkin et al., 2015; Postow et al., 2015) . However, blockade of PD-L1 plus CTLA-4 starting from day 30 post-transplant did not induce heart allograft rejection in Irf4 fl/fl Cd4-Cre recipients. Therefore, a progressive process must exist to establish the irreversible dysfunctional state of Irf4-deficient T cells. A very high proportion of polyclonal WT T cells ($0.1%-10%) in transplant recipients are able to recognize and respond to intact allogeneic MHC on donor APCs (termed direct allorecognition) or donor MHC peptides presented by recipient APCs (termed indirect allorecognition) (Lechler et al., 2005; Rogers and Lechler, 2001 deficiency and immune checkpoint blockade. Recent reports indicated that in patients with stable function of transplanted kidneys but also developed metastatic cancer, PD-1 blockade was used to treat cancer. Unfortunately, PD-1 blockade triggered acute rejection of the transplanted kidneys (Alhamad et al., 2016; Lipson et al., 2016) . Given that the late dysfunctional state of Irf4-deficient T cells was irreversible by checkpoint blockade, it would be interesting to know whether pharmaceutical IRF4 inhibition could be a potential therapeutic approach for transplantation. We found that trametinib was an effective inhibitor that diminished IRF4 expression in activated CD4 + T cells. Transient trametinib treatment abolished EAE development and prolonged allograft survival. Although further investigations are required to define the immune mechanism of action of trametinib, these results demonstrated the feasibility of targeting IRF4 expression for eliminating undesired T cell responses. In summary, IRF4 restrained the dysfunctional differentiation of CD4 + T cells, representing a novel role for IRF4 in linking TCR signaling to CD4 + T cell fates. Moreover, we introduced the concept of T cell dysfunction, which is mainly documented in chronic viral infection and tumor models, into research aiming to eliminate undesired T cells responses, such as transplant rejection and autoimmunity. Induction of T cell dysfunction by targeting IRF4 represents a potential therapeutic strategy for treatment of transplant rejection and autoimmune disorders.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
AUTHOR CONTRIBUTIONS
J.W., R.S., X.X., X.C.L., and W.C. conceived and designed the research. J.W. carried out most of the experiments with help from H.Z., X.S., X.X., and Y.F.; W.C. performed heart transplantations; and R.S. established the Irf4 À/À TEa mouse. J.W., R.S., X.X., L.J.M., R.M.G., J.W., J.X., X.C.L., and W.C. analyzed results and discussed the results, and W.C. and X.C.L. coordinated this work and wrote the manuscript. , I-E -) are specific for BALB/c allopeptide I-Ea 52-68 presented by B6 APCs and bound to I-A b . Male mice at 8 to 10 weeks of age were used for heart transplantation, and 10-week-old B6 female mice were subjected to EAE induction. Littermates of the same sex were randomly assigned to experimental groups. Mice were housed in a specific pathogen free facility at Houston Methodist Research Institute in Houston, Texas. All animal experiments in this study were approved by the Houston Methodist Animal Care Committee in accordance with institutional animal care and use guidelines.
STAR+METHODS KEY RESOURCES TABLE
METHOD DETAILS
Flow cytometry Splenocytes, lymph node cells, graft infiltrating cells (Chen et al., 2007) , CNS-infiltrating cells, and cultured T cells were stained and analyzed on the LSR II flow cytometer (Beckton Dickinson), and the resulting data was processed by using FlowJo v10 software (Tree Star, Inc.). Fluorochrome-conjugated antibodies used for flow cytometry were as follows: specific for mouse CD3 (clone 145-2C11), TCRb (H57-597), CD4 (GK1.5), CD8a (53-6.7), CD138 (281-2), GL7 (GL7), CD25 ( Murine heterotopic heart transplantation Heart transplantation in mice was performed by a previously described method (Miyahara et al., 2012; Chen et al., 2007) . In brief, hearts from BALB/c donors were transplanted into 8 to 10-week-old male WT B6, Irf4 fl/fl Cd4-Cre, CD45.1 + congenic, or Rag1 À/À recipient mice. Pulmonary artery and aorta of donor heart were cut open, remaining heart vessels were tied off, and heart was removed. Anesthetized recipient mouse was opened by the midline incision and blood flow of the abdominal aorta and inferior vena cava was interrupted by ligation with 6-0 silk thread. Incisions were made in recipient abdominal aorta and inferior vena cava to perform anastomosis with donor heart aorta and donor pulmonary artery, respectively. Anastomosis was made by 11-0 sutures running continuously. 6-0 silk thread was removed and abdomen was then closed by 5-0 sutures in two layers. Heart graft survival was monitored daily by palpation, and the day of complete cessation of heartbeat was considered as the day of rejection. Induction and assessment of EAE 10-week-old female B6 mice were subjected to EAE induction by using the Hooke Kit MOG 35-55 /CFA Emulsion PTX (EK-0113; Hooke Laboratories, Lawrence, MA) according to the manufacturer's instructions, and were orally gavaged with corn oil or 3 mg/kg trametinib every other day from day 0 to day 12 post immunization. Mice were monitored daily for the development of clinical signs of EAE and scored according to the previously reported criteria (Lee et al., 2012) . At 18-20 days post induction of EAE, mice were euthanized for flow cytometry analysis of T cells in CNS, spleen, and draining lymph nodes of the sites of immunization. Methods for isolation of CNS-infiltrating mononuclear cells have been previously reported (Lee et al., 2012; Xiao et al., 2016) . 
Polarization of CD4
+ T cells in vitro For Th17 polarization, WT naive CD4 + cells were activated for 3 days in the presence of 1 ng/ml human TGF-b1, 10 ng/ml mouse IL-6, 10 ng/ml IL-1b, 10 ng/ml IL-23, 5 mg/ml anti-IL-2 (JES6-1A12), 5 mg/ml anti-IL-4 (11B11), and 5 mg/ml anti-IFN-g (XMG 1.2), followed by flow cytometry analysis of IL-17A and IL-17F expressions. For some experiments cell cultures were supplemented with 0.2% DMSO or 100 nM trametinib. Recombinant cytokines were purchased from PeproTech and R&D systems, and cytokine-neutralizing antibodies were purchased from BioLegend. For Th1 polarization, WT naive CD4 + cells were activated for 3 days in the presence of 10 ng/ml IL-12 (PeproTech) and 5 mg/ml anti-IL-4. Cell cultures were treated with DMSO or 100 nM trametinib. IFN-g and IL-4 expressions were assessed by flow cytometry analysis. For iTreg polarization, FoxP3GFP À naive CD4 + T cells were activated for 3 days in the presence of 3 ng/ml TGF-b1. Cell cultures were treated with DMSO or 100 nM trametinib. FoxP3GFP expression was assessed by flow cytometry analysis.
In vitro suppression assay
The responder CD4 + T cells were isolated from CD45.1 + congenic mice by using the Dynabeads Untouched Mouse CD4 Cells Kit (Thermo Fisher Scientific), and then labeled with CTV. Dynabeads FlowComp Mouse CD4 + CD25 + Treg Cells Kit (Thermo Fisher Scientific) was used to isolate Treg cells from the spleens of naive B6 or Irf4 fl/fl Cd4-Cre mice, or from the spleens of Irf4 fl/fl Cd4-Cre recipients at day 7 after heart transplantation (treated with either Rat IgG or anti-CTLA-4 plus anti-PD-L1 mAbs). CTV-labeled CD45.1 + CD4 + T cells were added at1x10 5 cells/well in 96-well round bottom tissue-culture plates together with or without equal numbers of Treg cells from different groups, and stimulated with T cell-depleted mitomycin C-treated B6 splenocytes and 1 mg/ml soluble anti-CD3e mAb. Three days later, CD45.1 + CD4 + T cells were analyzed for proliferation by CTV dilution using a LSR II flow cytometer.
Quantitative RT-PCR Total RNA was extracted from activated WT and Irf4 À/À CD4 + T cells using a RNeasy mini kit (QIAGEN), and cDNA was synthesized using the iScript TM Reverse Transcription Supermix (Bio-rad). All target primers were predesigned KiCqStart Primers (Sigma-aldrich). Transcription of target genes was calculated according to the 2ÀDCT method as described by the manufacturer (CFX96 Touch RealTime PCR Detection System; Bio-rad). Gene expression results were expressed as arbitrary units relative to the expression of Gapdh.
Immunoblot analysis
Protein extracts were resolved by SDS-PAGE, transferred onto an Immunobilon membrane, and analyzed by immunoblot with anti-IRF4 (sc-6059; Santa Cruz), anti-BATF (8638; Cell Signaling Technology), and anti-b-actin (12262; Cell Signaling Technology). Horseradish peroxidase-linked antibody to rabbit immunoglobulin G (7074; Cell Signaling Technology), horseradish peroxidaselinked antibody to goat immunoglobulin G (sc-2768; Santa Cruz), and horseradish peroxidase-linked antibody to mouse immunoglobulin G (7076; Cell Signaling Technology) were used as secondary antibodies. Protein expression was detected by chemiluminescence.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were performed as previously described (Xiao et al., 2016) . All primers used in ChIP-PCR and the reported IRF4 binding site in Ikzf2 intron (Li et al., 2012) are displayed in Figure S3 . In brief, naive WT or Irf4 À/À CD4 + T cells were activated in vitro for 48 hours and then fixed with formaldehyde. Chromatin was extracted from 1x10 6 cells for each immunoprecipitation. Anti-Histone H3K9me3 (61013; Active Motif), anti-H3K4me3 (17-678; Millipore), anti-H3Ac (39139; Active Motif), anti-H4Ac (39925; Active Motif), anti-Helios (sc-9864; Santa Cruz), anti-IRF4 (sc-6059, Santa Cruz), and isotype-matched control antibody (sc-2027; Santa Cruz) were used for immunoprecipitation of chromatin with an EZ ChIP kit according to the manufacturer's instructions (Millipore). The precipitated DNA was then analyzed by real-time PCR. Data are presented as relative binding based on normalization to input DNA.
Retrovirus-mediated gene expression cDNA fragments encoding mouse Irf4 and Ikzf2 were amplified by PCR and then cloned into a pMYs-IRES-EGFP retroviral vector (Cell Biolabs). Retroviral particles were produced by transfecting plat-E cells with those retroviral vectors according to the manufacturer's recommendations (Cell Biolabs). For T cell transduction, naive WT or Irf4 À/À CD4 + T cells were activated for 24 hours with B6 APCs and 1 mg/ml soluble anti-CD3 mAb, and then incubated with freshly prepared retroviral particles by centrifugation for 2 hours at 780 g and 32 C in the presence of 8 mg/ml polybrene (Sigma-Aldrich). After centrifugation, cells were first cultured for 6 hours at 32 C, and subsequently cultured for additional 3 days in complete RPMI 1640 medium at 37 C prior to flow cytometry analysis. For preparing IRF4 re-introduced alloreactive Irf4 À/À CD4 + T cells, BALB/c splenic DCs were isolated by using the Pan Dendritic Cell Isolation Kit (Miltenyi Biotec). Irf4 À/À CD4 + T cells were activated for 3 days with BALB/c splenic DCs and 100 IU IL-2, and incubated with freshly prepared retroviral particles as mentioned above. Cells were cultured for one day after transduction, and then adoptively transferred into Irf4 fl/fl Cd4-Cre mice on day 1 post-heart transplantation.
Retrovirus-mediated Ikzf2 knockdown
The shRNA sequences for Ikzf2 were designed by using the online tool (https://rnaidesigner.thermofisher.com ). Five top listed shRNA sequences were selected and synthesized at IDT. Two complementary oligos were annealed at annealing buffer and ligated into shRNA vector (pSIREN-RetroQ-ZsGreen) from Clontech. After BamHI and EcoRI digestion, positive colonies were further verified by direct sequencing. The knockdown efficiency for each shRNA was measured in activated Irf4 À/À CD4 + T cells by FACS, and the most potent shRNAs (Target sequence: GCAGGTCATGAGTCACCATGT) were selected for performing the following experiment: Irf4 À/À CD4 + T cells were activated for 24 hours with B6 APCs and 1 mg/ml soluble anti-CD3 mAb, and then incubated with freshly prepared retroviral particles by centrifugation for 2 hours at 780 g and 32 C in the presence of 8 mg/ml polybrene. After centrifugation, cells were first cultured for 6 hours at 32 C, and subsequently cultured for additional 3 days in complete RPMI 1640 medium at 37 C prior to assessing Helios and PD-1 expressions.
Microarray and GO Enrichment Analysis
Microarray was performed by the Genomic and RNA Profiling Core at Baylor College of Medicine and data generated has been deposited in NCBI's Gene Expression Omnibus with accession number GSE83283. Naive CD4 + T cells (CD62L + CD44 À ) were sorted from WT B6 or Irf4 À/À mice a FACSAria flow cytometer, and activated in vitro with soluble anti-CD3 mAb (2C11) and mitomycin C-treated APCs in 96-well round bottom tissue-culture plates. Forty-eight hours later, living CD4 + T cells were sorted from cultures by flow cytometry. Total RNA was extracted with RNeasy mini kit (QIAGEN). RNA was quantified using a NanoDrop-1000 spectrophotometer and quality was monitored with the Agilent 2100 Bioanalyzer (Agilent Technologies). Cyanine-3 labeled cRNA was prepared from 0.5 mg RNA using the One-Color Low RNA Input Linear Amplification PLUS kit (Agilent Technologies) and hybridized to Agilent SurePrint G3 Mouse GE v2 8x60K Microarray (G4852B; 074809). Slides were scanned immediately after washing on the Agilent Technologies Scanner (G2505C). Data were normalized and analyzed using the Subio Platform (Subio). Gene Ontology (GO) enrichment was performed using PANTHER (Annotation Version: GO Ontology database Released 20150806).
QUANTIFICATION AND STATISTICAL ANALYSIS
Data were represented as mean ± SD and analyzed with Prism version 7.0a (GraphPad Software). The P values of EAE clinical scores and graft survival were determined by the Mann-Whitney test. Other measurements were performed using unpaired Student's t test. The sample size chosen for the animal experiments was estimated based on the literature and our previous experience of performing similar sets of experiments. Differences were considered significant when p < 0.05. P values are denoted in figures as follows: n.s., p > 0.05; *, p < 0.05; and **, p < 0.01.
DATA AND SOFTWARE AVAILABILITY
Microarray data for this project have been deposited at NCBI's Gene Expression Omnibus (GEO) with the accession number GSE83283.
